Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 27

Sort by

Sort Order Select

Journal Articles

Smoldering Multiple Myeloma in Latin America- Risk Stratification

Blood (2024) 144 (Supplement 1): 3774.

https://doi.org/10.1182/blood-2024-209038

Published: 2024

Journal Articles

Efficacy Outcomes By Minimal Residual Disease (MRD) Negativity in Patients with Relapsed or Refractory Multiple Myeloma Treated with Belantamab Mafodotin Plus Bortezomib and Dexamethasone Vs Daratumumab, Bortezomib, and Dexamethasone: Analysis from the Dreamm-7 Trial

Vania Hungria, Marek Hus, Pawel Robak, Vera Zherebtsova, Ana Carolina de Almeida Ribas, Marcelo Pitombeira de Lacerda, Kihyun Kim, Sebastian Grosicki, Irwindeep Sandhu, Christopher Ward, Astrid McKeown, Hena Baig, Jie Ma, Benjamin Lariviere, Benga Kazeem, Lydia Eccersley, Sumita Roy-Ghanta, Joanna Opalinska, Maria Victoria Mateos

Blood (2024) 144 (Supplement 1): 3359.

https://doi.org/10.1182/blood-2024-201543

Published: 2024

Journal Articles

Daratumumab-Based Quadruplet Versus Triplet Induction Regimens in Frontline Transplant-Eligible Newly Diagnosed Multiple Myeloma: A Systematic Review and Meta-Analysis

Joao Tadeu Damian Souto Filho, Lucas Oliveira Cantadori, Edvan De Queiroz Crusoe, Vania Hungria, Angelo Maiolino

Blood (2024) 144 (Supplement 1): 258.

https://doi.org/10.1182/blood-2024-202677

Published: 2024

Journal Articles

Subcutaneous Daratumumab (DARA) + Bortezomib, Cyclophosphamide, and Dexamethasone (VCd) in Patients with Newly Diagnosed Light Chain (AL) Amyloidosis: Overall Survival and Final Major Organ Deterioration Progression-Free Survival Results from the Phase 3 Andromeda Study

Blood (2024) 144 (Supplement 1): 891.

https://doi.org/10.1182/blood-2024-205077

Published: 2024

Journal Articles

Phase 3 Randomized Study of Daratumumab Monotherapy Versus Active Monitoring in Patients with High-Risk Smoldering Multiple Myeloma: Primary Results of the Aquila Study

Blood (2024) 144 (Supplement 1): 773.

https://doi.org/10.1182/blood-2024-201057

Published: 2024

Journal Articles

Belantamab Mafodotin, Bortezomib, and Dexamethasone Vs Daratumumab, Bortezomib, and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Overall Survival Analysis and Updated Efficacy Outcomes of the Phase 3 Dreamm-7 Trial

Blood (2024) 144 (Supplement 1): 772.

https://doi.org/10.1182/blood-2024-200336

Published: 2024

Journal Articles

Use of Teclistamab Outside of Clinical Trials in Latin America: Risk of Infections and Immunoglobulin Replacement

Fernando Vieira Pericole, Edvan Crusoe, Glaciano Ribeiro, Juliana Lima, Erica Lammerhirt Ottoni, Rafael Cunha, Abel Costa, Priscilla Cury, James Maciel, Vania Hungria

Blood (2024) 144 (Supplement 1): 7847.

https://doi.org/10.1182/blood-2024-209492

Published: 2024

Journal Articles

Phase 3 Study of Teclistamab (Tec) in Combination with Lenalidomide (Len) and Tec Alone Versus Len Alone in Newly Diagnosed Multiple Myeloma (NDMM) As Maintenance Therapy Following Autologous Stem Cell Transplantation (ASCT): Safety Run-in (SRI) Results from the Majestec-4/EMN30 Trial

Elena Zamagni, Tobias Silzle, Ivan Špička, Sabrin Tahri, Sarah Lonergan, Inger S. Nijhof, Antonietta Pia Falcone, Evangelos Terpos, Jakub Radocha, Roberto Mina, Guldane Cengiz Seval, Meral Beksac, Cesar Rodriguez, Marcelo C. Pasquini, Michel Delforge, Vania Hungria, Donna Reece, Philippe Moreau, Yael C. Cohen, Kihyun Kim, Dominik Dytfeld, Jiří Minařík, Irene Strassl, Jelena Bila, Martin Schreder, Janusz Krawczyk, Fredrik Schjesvold, Caroline Cicin-Sain, Christoph Driessen, Gordon Cook, Lugui Qiu, Gonzalo Martin Garate, Agoston Gyula Szabo, Roman Hájek, Marc S. Raab, Silvia Mangiacavalli, Hermann Einsele, Andrew Spencer, Mario Boccadoro, Helen Vassalou, Lixia Pei, Yingqi Shi, Maria Krevvata, Ryan Gruber, Caline Sakabedoyan, Margaret Cobb, Jagoda Jasielec, Himal Amin, Rachel Kobos, Pieter Sonneveld, Niels W.C.J. van de Donk

Blood (2024) 144 (Supplement 1): 494.

https://doi.org/10.1182/blood-2024-205608

Published: 2024

Journal Articles

Phase 3 Randomized Study of Daratumumab (DARA) + Bortezomib, Lenalidomide and Dexamethasone (VRd) Versus Alone in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma or for Whom Transplant Is Not Planned As Initial Therapy: Analysis of Minimal Residual Disease in the Cepheus Trial

Blood (2024) 144 (Supplement 1): 362.

https://doi.org/10.1182/blood-2024-200871

Published: 2024

Journal Articles

Prognostic value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE, and MAIA

Blood (2022) 139 (6): 835–844.

https://doi.org/10.1182/blood.2021011101

Published: 2022

Includes: Supplemental data

Journal Articles

Final Overall Survival Results from BELLINI, a Phase 3 Study of Venetoclax or Placebo in Combination with Bortezomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma

Shaji Kumar, Simon J Harrison, Michele Cavo, Javier de la Rubia, Rakesh Popat, Cristina J. Gasparetto, Vania Hungria, Hans Salwender, Kenshi Suzuki, Inho Kim, Maika Onishi, Grace Ku, Rajvineeth Kumar Pothacamury, Vasudha Sehgal, Abdullah A. Masud, Jeremy A. Ross, Edyta Dobkowska, Philippe Moreau

Blood (2021) 138 (Supplement 1): 84.

https://doi.org/10.1182/blood-2021-145757

Published: 2021

Journal Articles

Evaluation of Hematopoietic Stem Cell Product As a New Site for Minimal Residual Disease By Next Generation Flow in Multiple Myeloma

Herbert Henrique de Melo Santos, Glaciano Ribeiro, Allan de souza Santos, Marcos Chaves, Joanna Leal, Juliana Andrade Santos, Alessandro de M. Almeida, Marco Aurelio Salvino, Mariane Melo Santos, Vania Hungria, Maria da Gloria B. Arruda, Edvan De Queiroz Crusoe

Blood (2021) 138 (Supplement 1): 4927.

https://doi.org/10.1182/blood-2021-154129

Published: 2021

Journal Articles

COVID-19 in Multiple Myeloma Patients: Frequencies and Risk Factors for Hospitalization, Ventilatory Support, Intensive Care Admission and Mortality -Cooperative Registry from Grupo Brasileiro De Mieloma Multiplo (GBRAM)

Marcia Garnica, Edvan De Queiroz Crusoe, Glaciano Ribeiro, Rosane Bittencourt, Roberto José Pessoa Magalhães, Karla Richter Zanella, Abrahão Elias Hallack Neto, Juliana Lima, Caroline Sola, Emmanuella G Souza, Andre Magalhaes, Angelo Maiolino, Vania Hungria

Blood (2021) 138 (Supplement 1): 4104.

https://doi.org/10.1182/blood-2021-153629

Published: 2021

Journal Articles

Subcutaneous Daratumumab with Bortezomib, Cyclophosphamide, and Dexamethasone in Patients with Newly Diagnosed Light Chain (AL) Amyloidosis: 18-Month Analysis of the Phase 3 ANDROMEDA Study

Blood (2021) 138 (Supplement 1): 159.

https://doi.org/10.1182/blood-2021-146820

Published: 2021

Journal Articles

Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed By Ciltacabtagene Autoleucel Versus Vrd Followed By Lenalidomide and Dexamethasone (Rd) Maintenance in Patients with Newly Diagnosed Multiple Myeloma Not Intended for Transplant: A Randomized, Phase 3 Study (CARTITUDE-5)

Dominik Dytfeld, Binod Dhakal, Mounzer Agha, Salomon Manier, Michel Delforge, Steven Kuppens, Salma Afifi, William Deraedt, Agne Taraseviciute-Morris, Jordan M. Schecter, Jane Gilbert, Fevzi Yalniz, Erika Florendo, Lida Pacaud, Vania Hungria, Saad Z. Usmani, Maria-Victoria Mateos

Blood (2021) 138 (Supplement 1): 1835.

https://doi.org/10.1182/blood-2021-146210

Published: 2021

Journal Articles

Progression Free Survival (PFS) Analysis of Daratumumab (Dara), Cyclophosphamide, Thalidomide and Dexamethasone: A Quadruplet Intensified Treatment for Transplant Eligible Newly Diagnosed Multiple Myeloma (TE NDMM) Patients

Edvan De Queiroz Crusoe, Joanna Leal, Marco Aurelio Salvino, Larissa Ferreira Lucas, Juliana Andrade Santos, Herbert Henrique de Melo Santos, Alessandro de M. Almeida, Allan de souza Santos, Marcos Chaves, Mariane Melo Santos, Sarah Queiroz Silva, Lucas de Oliveira Vieira, Cleverson Alves Fonseca, Elisangela Adorno, Vania Hungria, Maria da Gloria B. Arruda

Blood (2021) 138 (Supplement 1): 3943.

https://doi.org/10.1182/blood-2021-150607

Published: 2021

Journal Articles

Subgroup Analysis: Efficacy and Safety of Panobinostat in Combination with SC Bortezomib and Oral Dexamethasone in Multiple Myeloma Patients with Lenalidomide-Refractory Disease

Joshua Richter, Jacob P. Laubach, Steve Stricker, Fredrik H. Schjesvold, David Cohan, Anna Sureda, Ewa Lech-Marańda, Meral Beksac, Vania Hungria, Meletios A. Dimopoulos, Ajai Chari, Paul G. Richardson, Philippe Moreau

Blood (2021) 138 (Supplement 1): 3759.

https://doi.org/10.1182/blood-2021-153694

Published: 2021

Journal Articles

Isatuximab as monotherapy and combined with dexamethasone in patients with relapsed/refractory multiple myeloma

Meletios Dimopoulos, Sara Bringhen, Pekka Anttila, Marcelo Capra, Michele Cavo, Craig Cole, Cristina Gasparetto, Vania Hungria, Matthew Jenner, Vladimir Vorobyev, Eduardo Yanez Ruiz, Jian Y. Yin, Rao Saleem, Maeva Hellet, Sandrine Macé, Bruno Paiva, Ravi Vij

Blood (2021) 137 (9): 1154–1165.

https://doi.org/10.1182/blood.2020008209

Published: 2021

Includes: Supplemental data

Journal Articles

Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data set

Blood (2020) 136 (26): 3033–3040.

https://doi.org/10.1182/blood.2020008150

Published: 2020

Includes: Supplemental data

Journal Articles

IgM Myeloma: A Multicenter Retrospective Study of 159 Patients

Blood (2016) 128 (22): 3276.

https://doi.org/10.1182/blood.V128.22.3276.3276

Published: 2016

NARROW

Smoldering Multiple Myeloma in Latin America- Risk Stratification

Efficacy Outcomes By Minimal Residual Disease (MRD) Negativity in Patients with Relapsed or Refractory Multiple Myeloma Treated with Belantamab Mafodotin Plus Bortezomib and Dexamethasone Vs Daratumumab, Bortezomib, and Dexamethasone: Analysis from the Dreamm-7 Trial

Daratumumab-Based Quadruplet Versus Triplet Induction Regimens in Frontline Transplant-Eligible Newly Diagnosed Multiple Myeloma: A Systematic Review and Meta-Analysis

Subcutaneous Daratumumab (DARA) + Bortezomib, Cyclophosphamide, and Dexamethasone (VCd) in Patients with Newly Diagnosed Light Chain (AL) Amyloidosis: Overall Survival and Final Major Organ Deterioration Progression-Free Survival Results from the Phase 3 Andromeda Study

Phase 3 Randomized Study of Daratumumab Monotherapy Versus Active Monitoring in Patients with High-Risk Smoldering Multiple Myeloma: Primary Results of the Aquila Study

Belantamab Mafodotin, Bortezomib, and Dexamethasone Vs Daratumumab, Bortezomib, and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Overall Survival Analysis and Updated Efficacy Outcomes of the Phase 3 Dreamm-7 Trial

Use of Teclistamab Outside of Clinical Trials in Latin America: Risk of Infections and Immunoglobulin Replacement

Phase 3 Study of Teclistamab (Tec) in Combination with Lenalidomide (Len) and Tec Alone Versus Len Alone in Newly Diagnosed Multiple Myeloma (NDMM) As Maintenance Therapy Following Autologous Stem Cell Transplantation (ASCT): Safety Run-in (SRI) Results from the Majestec-4/EMN30 Trial

Phase 3 Randomized Study of Daratumumab (DARA) + Bortezomib, Lenalidomide and Dexamethasone (VRd) Versus Alone in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma or for Whom Transplant Is Not Planned As Initial Therapy: Analysis of Minimal Residual Disease in the Cepheus Trial

Prognostic value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE, and MAIA

Final Overall Survival Results from BELLINI, a Phase 3 Study of Venetoclax or Placebo in Combination with Bortezomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma

Evaluation of Hematopoietic Stem Cell Product As a New Site for Minimal Residual Disease By Next Generation Flow in Multiple Myeloma

COVID-19 in Multiple Myeloma Patients: Frequencies and Risk Factors for Hospitalization, Ventilatory Support, Intensive Care Admission and Mortality -Cooperative Registry from Grupo Brasileiro De Mieloma Multiplo (GBRAM)

Subcutaneous Daratumumab with Bortezomib, Cyclophosphamide, and Dexamethasone in Patients with Newly Diagnosed Light Chain (AL) Amyloidosis: 18-Month Analysis of the Phase 3 ANDROMEDA Study

Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed By Ciltacabtagene Autoleucel Versus Vrd Followed By Lenalidomide and Dexamethasone (Rd) Maintenance in Patients with Newly Diagnosed Multiple Myeloma Not Intended for Transplant: A Randomized, Phase 3 Study (CARTITUDE-5)

Progression Free Survival (PFS) Analysis of Daratumumab (Dara), Cyclophosphamide, Thalidomide and Dexamethasone: A Quadruplet Intensified Treatment for Transplant Eligible Newly Diagnosed Multiple Myeloma (TE NDMM) Patients

Subgroup Analysis: Efficacy and Safety of Panobinostat in Combination with SC Bortezomib and Oral Dexamethasone in Multiple Myeloma Patients with Lenalidomide-Refractory Disease

Isatuximab as monotherapy and combined with dexamethasone in patients with relapsed/refractory multiple myeloma

Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data set

IgM Myeloma: A Multicenter Retrospective Study of 159 Patients

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only